Literature DB >> 24401885

Long-term results of mucosal advancement flap combined with platelet-rich plasma for high cryptoglandular perianal fistulas.

Kevin W Göttgens1, Wouter Vening, Stefan J van der Hagen, Wim G van Gemert, Reinier R Smeets, Laurents P Stassen, Cor G Baeten, Stephanie O Breukink.   

Abstract

BACKGROUND: The long-term closure rate of high perianal fistulas after surgical treatment remains disappointing.
OBJECTIVE: The goal of this study was to improve the long-term closure rate of high cryptoglandular perianal fistulas combining mucosal advancement flap with platelet-rich plasma.
DESIGN: This study was retrospective in design.
SETTING: This study was conducted at 2 secondary and 1 tertiary referral hospitals. PATIENTS: Patients presenting with high cryptoglandular perianal fistulas involving the middle/upper third of the anal sphincter complex were included.
INTERVENTIONS: A staged surgical treatment was performed; After seton placement, a mucosal advancement flap was combined with platelet-rich plasma. MAIN OUTCOME MEASURES: Recurrence was the main outcome. Incontinence was the secondary outcome.
RESULTS: We operated on 25 patients between 2006 and 2012. Thirteen (52%) patients had previous fistula surgery. The median follow-up period was 27 months. One patient (4.0%) was lost to follow-up after 4 months. Freedom from recurrence at 2 years was 0.83 (95% CI, 0.62-0.93). Two of the 4 patients with a recurrence (8%) had a repeated treatment and healed. One patient (4.0%) refused another treatment, but agreed to stay in follow-up. One patient (4.0%) requested a colostomy, resulting in closure of the fistula. Complications occurred in 1 patient (4.0%). Incontinence numbers were low with a median Vaizey score of 3.0 out of a maximum of 24. LIMITATIONS: The study was limited by its retrospective design, lack of preoperative incontinence data, selection bias, and phone interview follow-up.
CONCLUSION: The long-term outcome results of patients with primary and recurrent high cryptoglandular perianal fistulas treated with a seton followed by mucosal advancement flap and platelet-rich plasma show low recurrence, complication, and incontinence rates. Therefore, this technique seems to be a valid option as treatment. Larger and preferably randomized controlled studies are needed to further explore this surgical technique.

Entities:  

Mesh:

Year:  2014        PMID: 24401885     DOI: 10.1097/DCR.0000000000000023

Source DB:  PubMed          Journal:  Dis Colon Rectum        ISSN: 0012-3706            Impact factor:   4.585


  6 in total

1.  Treatment of transsphincteric fistula-in-ano with growth factors from autologous platelets: results of a phase II clinical trial.

Authors:  F de la Portilla; J J Segura-Sampedro; M L Reyes-Díaz; M V Maestre; A M Cabrera; R M Jimenez-Rodríguez; J M Vázquez-Monchul; J M Diaz-Pavón; F J Padillo-Ruiz
Journal:  Int J Colorectal Dis       Date:  2017-07-29       Impact factor: 2.571

2.  Long-term outcome of low perianal fistulas treated by fistulotomy: a multicenter study.

Authors:  K W A Göttgens; P T J Janssen; J Heemskerk; F M H van Dielen; J L M Konsten; T Lettinga; A G M Hoofwijk; H J Belgers; L P S Stassen; S O Breukink
Journal:  Int J Colorectal Dis       Date:  2014-11-25       Impact factor: 2.571

Review 3.  Systematic review and meta-analysis of surgical interventions for high cryptoglandular perianal fistula.

Authors:  K W A Göttgens; R R Smeets; L P S Stassen; G Beets; S O Breukink
Journal:  Int J Colorectal Dis       Date:  2014-12-10       Impact factor: 2.571

Review 4.  Heterogeneity in outcome selection, definition and measurement in studies assessing the treatment of cryptoglandular anal fistula: findings from a systematic review.

Authors:  A J H M Machielsen; N Iqbal; M L Kimman; K Sahnan; S O Adegbola; G Kane; R Woodcock; J Kleijnen; U Grossi; S O Breukink; P J Tozer
Journal:  Tech Coloproctol       Date:  2021-05-08       Impact factor: 3.781

5.  Treatment of Crohn's disease-related high perianal fistulas combining the mucosa advancement flap with platelet-rich plasma: a pilot study.

Authors:  K W A Göttgens; R R Smeets; L P S Stassen; G L Beets; M Pierik; S O Breukink
Journal:  Tech Coloproctol       Date:  2015-05-15       Impact factor: 3.781

6.  Pro-inflammatory cytokines in cryptoglandular anal fistulas.

Authors:  R S van Onkelen; M P Gosselink; M van Meurs; M J Melief; W R Schouten; J D Laman
Journal:  Tech Coloproctol       Date:  2016-07-11       Impact factor: 3.781

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.